The role of pharmacoeconomic evaluations in disease management.

Abstract:

:Disease management is a systematic approach to a health condition or a healthcare intervention that organises preventative, interventional and care approaches throughout the continuum of care and which measures outcomes in terms of populations, not individuals. Disease management's advantage over the current component system is that it stresses prevention over acute treatment of a chronic disease. Patients with better control of their chronic diseases will likely have a decrease in the use of emergency room and inpatient hospitalisation services, thereby improving clinical outcomes of patients. To achieve these goals, disease management uses pharmacoeconomic evaluations and outcomes measures to provide information that helps build formularies and clinical practice guidelines. Several problems exist in integrating pharmacoeconomic studies in disease management models, such as the need for more integrated information systems, standardisation and who should perform these evaluations. Some possible solutions will be addressed in this article. With greater emphasis being placed on controlling costs, the need for pharmacoeconomic evaluations in the design of disease management models will continue to increase in the future.

journal_name

Pharmacoeconomics

journal_title

PharmacoEconomics

authors

Chang K,Nash D

doi

10.2165/00019053-199814010-00002

subject

Has Abstract

pub_date

1998-07-01 00:00:00

pages

11-7

issue

1

eissn

1170-7690

issn

1179-2027

journal_volume

14

pub_type

杂志文章,评审
  • Measurement of health-related QOL in diabetes mellitus.

    abstract::A number of health-related QOL (HR-QOL) measures specifically designed for people with diabetes mellitus have appeared in the literature. This article provides a selective review of 12 measures that address this important construct. For each included study, a description of the measure and its development phase is pro...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-200422170-00002

    authors: Watkins K,Connell CM

    更新日期:2004-01-01 00:00:00

  • Pharmacoeconomics of intravenous drug administration.

    abstract::Direct administration of a drug into a vein guarantees bioavailability, i.e. the total amount of drug is fully available to the bloodstream for transport to all areas of the body. What is not ensured is the safety, need and 'value for money' of this route. Few workers would disagree that there is increased morbidity...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-199201020-00007

    authors: Parker SE,Davey PG

    更新日期:1992-02-01 00:00:00

  • The Clinical and Cost Effectiveness of Inotuzumab Ozogamicin for the Treatment of Adult Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.

    abstract::The National Institute for Health and Care Excellence (NICE) invited Pfizer, the manufacturer of inotuzumab ozogamicin (henceforth inotuzumab), to submit clinical- and cost-effectiveness evidence for inotuzumab as part of NICE's single technology appraisal process. The Centre for Reviews and Dissemination and the Cent...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.1007/s40273-019-00779-4

    authors: Cox E,Wade R,Peron M,Dietz KC,Eastwood A,Palmer S,Griffin S

    更新日期:2019-09-01 00:00:00

  • Time trends and determinants of pharmaceutical expenditure in China (1990-2009).

    abstract:BACKGROUND:Pharmaceutical policy reform is currently one of the primary areas of health reform in China. The national pharmaceutical policy of China has multiple objectives: to develop the domestic pharmaceutical industry and encourage innovation, to control escalation of total pharmaceutical expenditures (TPE) which c...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-013-0072-3

    authors: Shi L,Yang HY,Cheng G,Meng Q

    更新日期:2014-03-01 00:00:00

  • Economic burden of multiple sclerosis: a systematic review of the literature.

    abstract::Multiple sclerosis (MS) is a disease of the CNS, typically striking adults during the primary productive time of their life. The symptoms of MS can restrict the individual's physical activity and income-earning ability, resulting in a major financial burden on the patient, family, health system and society. This syste...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,meta分析,评审

    doi:10.2165/11532230-000000000-00000

    authors: Naci H,Fleurence R,Birt J,Duhig A

    更新日期:2010-01-01 00:00:00

  • The Use of Mapping to Estimate Health State Utility Values.

    abstract::Mapping functions are estimated using regression analyses and are frequently used to predict health state utility values (HSUVs) in decision analytic models. Mapping functions are used when evidence on the required preference-based measure (PBM) is not available, or where modelled values are required for a decision an...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.1007/s40273-017-0548-7

    authors: Ara R,Rowen D,Mukuria C

    更新日期:2017-12-01 00:00:00

  • Testing the validity of cost-effectiveness models.

    abstract::A growing body of recent work has identified several problems with economic evaluations undertaken alongside controlled trials that can have potentially serious impacts on the ability of decision makers to draw valid conclusions. At the same time, the use of cost-effectiveness models has been drawn into question, due ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-200017050-00007

    authors: McCabe C,Dixon S

    更新日期:2000-05-01 00:00:00

  • Cost effectiveness of adding ezetimibe to atorvastatin therapy in patients not at cholesterol treatment goal in Canada.

    abstract:INTRODUCTION:This analysis compared the cost effectiveness of adding ezetimibe to atorvastatin therapy versus atorvastatin titration or adding cholestyramine (a resin) for patients at high risk of a coronary artery disease (CAD) event who did not reach target cholesterol levels on their current atorvastatin dosage. The...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200624080-00007

    authors: Kohli M,Attard C,Lam A,Huse D,Cook J,Bourgault C,Alemao E,Yin D,Marentette M

    更新日期:2006-01-01 00:00:00

  • Clinical aspects of therapeutic substitution.

    abstract::A variety of problems are associated with the operation, quality, costs, and benefits of therapeutic substitution programmes. Adequate communication of procedures, events, and failures are essential features of a safe therapeutic substitution policy. However, case reports of suboptimal therapy and differences in pha...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-199200011-00010

    authors: Levy RA

    更新日期:1992-01-01 00:00:00

  • Cost-Effectiveness Analysis of Patiromer in Combination with Renin-Angiotensin-Aldosterone System Inhibitors for Chronic Kidney Disease in Sweden.

    abstract:OBJECTIVES:Patients with chronic kidney disease (CKD) are commonly treated with renin-angiotensin-aldosterone system inhibitors (RAASi) in order to delay progression of renal disease. However, research has shown that RAASi in CKD patients increases hyperkalaemia (HK) prevalence, which leads to RAASi discontinuation or ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-020-00902-w

    authors: Widén J,Ivarsson M,Schalin L,Vrouchou P,Schwenkglenks M,Heimbürger O,Ademi Z,Sutherland CS

    更新日期:2020-07-01 00:00:00

  • On individual preferences and aggregation in economic evaluation in healthcare.

    abstract::For practical reasons, in order to carry out economic evaluations of collective decisions, total costs will generally be compared with total benefits; hence, individuals' willingness to pay (WTP) or quality-adjusted life-years (QALYs) have to be estimated at an aggregate level. So far, aggregation has usually been don...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-200119040-00001

    authors: Liljas B,Lindgren B

    更新日期:2001-01-01 00:00:00

  • Anaemia of prematurity. Epidemiology, management and costs.

    abstract::Recombinant human erythropoietin (rHuEpo) has been increasingly used in preterm infants in the last 3 to 4 years. Recent studies have indicated a reduction in blood transfusion requirements in infants receiving rHuEpo. No significant adverse effects have emerged, apart from iron deficiency (if iron supplementation is ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-199712040-00002

    authors: Meyer MP

    更新日期:1997-10-01 00:00:00

  • Selective versus nonselective beta adrenoceptor antagonists in hypertension.

    abstract::The application of cost-effectiveness methodology is particularly important in widespread diseases such as hypertension. However, because prospective cost-effectiveness analyses comparing different antihypertensive drugs are not currently available, differences in the cost effectiveness of these drugs can only be esti...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-199508060-00006

    authors: Van Bortel LM,Ament AJ

    更新日期:1995-12-01 00:00:00

  • Performance of the UKPDS Outcomes Model 2 for Predicting Death and Cardiovascular Events in Patients with Type 2 Diabetes Mellitus from a German Population-Based Cohort.

    abstract:BACKGROUND AND OBJECTIVE:Accurate prediction of relevant outcomes is important for targeting therapies and to support health economic evaluations of healthcare interventions in patients with diabetes. The United Kingdom Prospective Diabetes Study (UKPDS) risk equations are some of the most frequently used risk equation...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-019-00822-4

    authors: Laxy M,Schöning VM,Kurz C,Holle R,Peters A,Meisinger C,Rathmann W,Mühlenbruch K,Kähm K

    更新日期:2019-12-01 00:00:00

  • Direct and indirect costs attributable to alcohol consumption in Germany.

    abstract:AIM:To estimate the direct and indirect costs of morbidity and mortality attributable to alcohol consumption in Germany from a societal perspective in 2002. METHODS:Using the concept of attributable risks and the prevalence-based approach, age- and gender-specific alcohol-attributable fractions for morbidity and morta...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200725070-00006

    authors: Konnopka A,König HH

    更新日期:2007-01-01 00:00:00

  • A systematic review to assess the policy-making relevance of dementia cost-of-illness studies in the US and Canada.

    abstract::A systematic review of dementia cost-of-illness (COI) studies in the US and Canada was conducted to explore the policy-making relevance of these studies. MEDLINE, CINAHL, EconLit, AMED and the Cochrane Library were searched from inception to March 2010 for English-language COI articles. Content analysis was used to ex...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/11539450-000000000-00000

    authors: Oremus M,Aguilar SC

    更新日期:2011-02-01 00:00:00

  • Assessing the economic value of a new antidepressant. A willingness-to-pay approach.

    abstract::Using the method of willingness to pay (WTP), this study assesses the value of a new antidepressant, moclobemide, relative to that of tricyclic antidepressants (TCAs), which have equivalent efficacy but less favourable adverse effect profiles. From a published meta-analysis of controlled clinical trials, we identified...

    journal_title:PharmacoEconomics

    pub_type: 临床试验,杂志文章

    doi:10.2165/00019053-199508010-00006

    authors: O'Brien BJ,Novosel S,Torrance G,Streiner D

    更新日期:1995-07-01 00:00:00

  • Cost effectiveness of epoetin-alpha to augment preoperative autologous blood donation in elective cardiac surgery.

    abstract:OBJECTIVE:The objective of this study was to assess the cost effectiveness of using epoetin-alpha (erythropoietin) to augment preoperative autologous donation (PAD) of blood prior to elective cardiac surgery. DESIGN AND SETTING:We designed a decision-analytic model incorporating the risk of receiving allogeneic blood,...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200018020-00006

    authors: Coyle D,Lee KM,Fergusson DA,Laupacis A

    更新日期:2000-08-01 00:00:00

  • Access with evidence development schemes: a framework for description and evaluation.

    abstract::There is an inevitable tension between robust reimbursement processes and providing speedy access to new and novel technologies, given uncertainties about key pieces of evidence and subsequent concerns regarding their overall efficiency. The public perception of these treatments as 'breakthrough', combined with substa...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/11530850-000000000-00000

    authors: McCabe CJ,Stafinski T,Edlin R,Menon D,Banff AED Summit.

    更新日期:2010-01-01 00:00:00

  • Unrelated medical costs in life-years gained: should they be included in economic evaluations of healthcare interventions?

    abstract::Which costs and benefits to consider in economic evaluations of healthcare interventions remains an area of much controversy. Unrelated medical costs in life-years gained is an important cost category that is normally ignored in economic evaluations, irrespective of the perspective chosen for the analysis. National gu...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-200826100-00003

    authors: Rappange DR,van Baal PH,van Exel NJ,Feenstra TL,Rutten FF,Brouwer WB

    更新日期:2008-01-01 00:00:00

  • Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers.

    abstract:BACKGROUND:Of 1 346 700 total deaths each year in the US, an estimated 440 100 are smoking related, making it the leading preventable cause of premature death in the US. Despite the health and economic benefits of smoking cessation being well documented, reimbursement coverage for smoking cessation therapies is general...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200826060-00004

    authors: Howard P,Knight C,Boler A,Baker C

    更新日期:2008-01-01 00:00:00

  • Treatment costs and quality of life with granulocyte-macrophage colony-stimulating factor in patients with antineoplastic therapy-related febrile neutropenia. Results of a randomised placebo-controlled trial.

    abstract::This study examined the costs of treatment of, and quality of life in, patients with antineoplastic therapy-induced neutropenic fever who were treated with antibacterials, with or without granulocyte-macrophage colony-stimulating factor (GM-CSF). Patients with haematological malignancies (n = 47) or solid tumours (n =...

    journal_title:PharmacoEconomics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00019053-199712030-00007

    authors: Uyl-de Groot CA,Vellenga E,de Vries EG,Löwenberg B,Stoter GJ,Rutten FF

    更新日期:1997-09-01 00:00:00

  • Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal.

    abstract::The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of denosumab (Amgen Inc., UK) to submit evidence for the clinical and cost effectiveness of denosumab for the prevention of fragility fractures in post-menopausal women, as part of the Institute's single technology appraisal (STA...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/11589310-000000000-00000

    authors: Scotland G,Waugh N,Royle P,McNamee P,Henderson R,Hollick R

    更新日期:2011-11-01 00:00:00

  • Cost-minimisation analysis of sequential treatment with ofloxacin or ciprofloxacin in hospitalised patients.

    abstract::This study evaluated the cost of sequential treatment with once-daily ofloxacin or twice-daily ciprofloxacin in 474 hospitalised patients in different countries. The patients were treated intravenously for at least 3 days, then orally for 7 to 10 days or for 3 days beyond the disappearance of infection-related symptom...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-199711040-00007

    authors: Salewski E,Bassaris HP,Calangu S,Kitzes R,Kosmidis J,Raz R,Kompan L

    更新日期:1997-04-01 00:00:00

  • Discounting in Economic Evaluations.

    abstract::Appropriate discounting rules in economic evaluations have received considerable attention in the literature and in national guidelines for economic evaluations. Rightfully so, as discounting can be quite influential on the outcomes of economic evaluations. The most prominent controversies regarding discounting involv...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.1007/s40273-018-0672-z

    authors: Attema AE,Brouwer WBF,Claxton K

    更新日期:2018-07-01 00:00:00

  • The future of health technology assessment in healthcare decision making in Asia.

    abstract::Most countries have healthcare resource constraints and it is easy to identify new health technologies as an area in need of resource management, particularly given that new health technologies usually increase rather than save costs. Resource constraints are even more noticeable in Asia than in other regions, with a ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/11310280-000000000-00000

    authors: Yang BM

    更新日期:2009-01-01 00:00:00

  • Refitting of the UKPDS 68 risk equations to contemporary routine clinical practice data in the UK.

    abstract:OBJECTIVE:Economic evaluations of new diabetes therapies rely heavily upon the UK Prospective Diabetes Study (UKPDS) equations for prediction of cardiovascular events; however, concerns persist regarding their relevance to current clinical practice and appropriate use in populations other than newly diagnosed patients....

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-014-0225-z

    authors: McEwan P,Bennett H,Ward T,Bergenheim K

    更新日期:2015-02-01 00:00:00

  • Applying recent findings to clinical care in type II diabetes.

    abstract::There is a global perspective to the economic consequences of diabetes, which is illustrated in the many publications now being produced on this subject. Because of the higher prevalence of type II diabetes, its impact is greater than that of type I diabetes in both developed and developing countries (but particularly...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-199500081-00017

    authors: Williams R

    更新日期:1995-01-01 00:00:00

  • Relationships between sponsors and investigators in pharmacoeconomic and clinical research.

    abstract::Potential conflict between the goals of the investigators and the sponsors of pharmacoeconomic and clinical research has been well documented. Although there have been efforts to formalise relationships between sponsors and investigators in some areas of clinical research, no set of guidelines or standardised contract...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-199507030-00004

    authors: Schulman KA,Rubenstein LE,Glick HA,Eisenberg JM

    更新日期:1995-03-01 00:00:00

  • What's good and bad about contraceptive products?: a best-worst attribute experiment comparing the values of women consumers and GPs.

    abstract:BACKGROUND:In the past decade, the range of contraceptives available has increased dramatically. There are limited data on the factors that determine women's choices on contraceptive alternatives or what factors providers consider most important when recommending contraceptive products to women. OBJECTIVES:Our objecti...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/11598040-000000000-00000

    authors: Knox SA,Viney RC,Street DJ,Haas MR,Fiebig DG,Weisberg E,Bateson D

    更新日期:2012-12-01 00:00:00